Reversal of Cushing's Syndrome by Vandetanib in Medullary Thyroid Carcinoma

Camille Baudry,Anne-Cécile Paepegaey,Lionel Groussin

Reversal of Cushing's Syndrome by Vandetanib in Medullary Thyroid Carcinoma

2013

Camille Baudry
Anne-Cécile Paepegaey
Lionel Groussin

A patient with refractory Cushing's syndrome due to corticotropin production by a medullary thyroid cancer had a quick response to vandetanib even before tumor shrinkage was evident.

Keywords:

Medullary cavity
Thyroid
Carcinoma
Vandetanib
Internal medicine
Endocrinology
Medullary thyroid cancer
Diabetes mellitus
Medicine
s syndrome
thyroid carcinoma
tumor shrinkage
Oncology
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations